Table 3.
Histopathological lesions | Our study | Olowu et al. [10] | Kari et al. [11] | Gulati et al. [12] | Azhar et al. [16] |
---|---|---|---|---|---|
FSGS | 38.7 | 39.1% | 39 | 58.8 | 28.8 |
MCD | 23.1 | 4.3 | 8 | 17.6 | 13.3 |
IgMN | 13.6 | — | 28 | — | 17.6 |
MesPGN | 10.2 | 8.7 | 17 | 17.6 | 8.8 |
MN | 8.2 | 4.3 | — | 1.4 | 13.3 |
MPGN | 4.8 | 43.5 | — | 1.6 | 11.5 |
IgAN | 0.6 | — | 3 | — | 6.6 |
FSGS: focal segmental glomerulosclerosis; IgANL: IgA nephropathy; IgMN: IgM nephropathy; MCD: minimal change disease; MesPGN: mesangioproliferative GN; MN: membranous GN; MPGN: mesangiocapillary or membranoproliferative GN.